GlassScriptPhysician profile
Jason Ballin
NPI 1235293820
$5,287.66
in general payments reported to CMS, 2019-2025
28 companies · $880 in 2025
The $880 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $331 · 2021: $400 · 2022: $735 · 2023: $1,144 · 2024: $1,281 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.07 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,275.94 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $713.24 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $521.44 | 2019-2025 | |
| Genzyme Corporation | $475.87 | 2019-2025 | |
| Amgen INC. | $393.19 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $292.64 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $246.91 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $210.09 | 2019-2024 | Dupixent, Libtayo |
| Pfizer INC. | $175.26 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $137.13 | 2019-2022 | |
| Leo Pharma INC. | $111.93 | 2019-2025 | Spevigo, Anzupgo |
| Galderma Laboratories, L.P. | $97.16 | 2020-2025 | Nemluvio |
| Incyte Corporation | $95.02 | 2022-2023 | Opzelura |
| Ucb, INC. | $84.99 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.25 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $63.52 | 2020 | |
| Mallinckrodt Hospital Products INC. | $54.88 | 2025 | Acthar |
| Almirall LLC | $38.62 | 2023 | Klisyri |
| Sun Pharmaceutical Industries INC. | $36.09 | 2022-2025 | |
| Dermavant Sciences, INC. | $31.14 | 2023-2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $25.84 | 2019 | |
| Merck Sharp & Dohme LLC | $25.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2024 | Spevigo |
| Krystal Biotech INC | $21.22 | 2025 | Vyjuvek |
| Nabriva Therapeutics, Plc | $19.00 | 2021 | |
| Arcutis Biotherapeutics, INC. | $18.97 | 2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $16.56 | 2020 | |
| Dermira, INC. | $14.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ballin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.